Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early …GlobeNewswire (press release)The Providence Cancer Institute translational medicine team conducted two phase 1 clinical trials, initiated under d… Continue reading
Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early …GlobeNewswire (press release)The Providence Cancer Institute translational medicine team conducted two phase 1 clinical trials, initiated under d… Continue reading
New CRISPR Kits Simplify Gene EditingPR Newswire (press release)ST. LOUIS, Nov. 13, 2017 /PRNewswire/ — Canopy Biosciences™, LLC, a provider of technologies for gene editing and personalized medicine, announced today that it has launched CRISPR Comple… Continue reading
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy …PR Newswire (press release)BOULDER, Colo., Nov. 13, 2017 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company f… Continue reading
Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy …PR Newswire (press release)BOULDER, Colo., Nov. 13, 2017 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY), a biopharmaceutical company f… Continue reading
Philadelphia Business JournalTemple spinout obtains exclusive license for CRISPR gene-editing toolPhiladelphia Business JournalPhiladelphia-based Excision BioTherapeutics said Monday it has become the first company to secure an exclusive license from t… Continue reading
|
CRISPR Therapeutics (CRSP) Names Michael Tomsicek as CFO
StreetInsider.com CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the appointment of Michael Tomsicek as Chief Financial Officer. Mr. Tomsicek is a highly … Equities Analysts Offer Predictions for Crispr Theraptc’s FY2017 Earnings (CRSP)Dispatch Tribunal Head to Head Analysis: Crispr Theraptc (CRSP) versus The CompetitionWeek Herald Crispr Theraptc (CRSP) Receives Hold Rating from SunTrust Banks, Inc.BBNS Analyst Ratings all 13 news articles » |